253 related articles for article (PubMed ID: 34598059)
1. Concurrent versus sequential chemoradiotherapy for unresectable locally advanced stage III non-small cell lung cancer: Retrospective analysis in a single United Kingdom cancer centre.
Spencer A; Williams J; Samuel R; Boon IS; Clarke K; Jain P
Cancer Treat Res Commun; 2021; 29():100460. PubMed ID: 34598059
[TBL] [Abstract][Full Text] [Related]
2. [Concurrent chemoradiotherapy followed by consolidation chemotherapy and sequential chemoradiotherapy for stage III non-small cell lung cancer: comparison in 93 patients].
Sun WZ; Song LP; Zhang YB; Ai T; Lu JL; Ren J; Gao Y
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Mar; 32(3):362-7. PubMed ID: 22445984
[TBL] [Abstract][Full Text] [Related]
3. Sequential chemoradiotherapy with accelerated hypofractionated radiotherapy compared to concurrent chemoradiotherapy with standard radiotherapy for locally advanced non-small cell lung cancer.
Zhu ZF; Ma HL; Fan M; Bao Y; Zhuang TT; Chen M; Jiang GL; Fu XL
Technol Cancer Res Treat; 2014 Jun; 13(3):269-75. PubMed ID: 24066952
[TBL] [Abstract][Full Text] [Related]
4. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center.
Shrimali RK; Nallathambi C; Saha A; Das A; Prasath S; Mahata A; Arun B; Mallick I; Achari R; Dabkara D; Thambudorai R; Chatterjee S
Indian J Cancer; 2018; 55(2):125-133. PubMed ID: 30604722
[TBL] [Abstract][Full Text] [Related]
5. Sequential Versus Concurrent Chemoradiation Therapy by Surgical Margin Status in Resected Non-Small Cell Lung Cancer.
Verma V; Moreno AC; Haque W; Fang P; Lin SH
J Natl Compr Canc Netw; 2018 May; 16(5):508-516. PubMed ID: 29752325
[No Abstract] [Full Text] [Related]
6. Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?
Hendriks LEL; Brouns -JWM; Amini M; Uyterlinde W; Wijsman R; Bussink J; Biesma B; Oei SB; Stigt JA; Bootsma GP; Belderbos JSA; De Ruysscher DKM; Van den Heuvel MM; Dingemans AC
Lung Cancer; 2016 Nov; 101():68-75. PubMed ID: 27794410
[TBL] [Abstract][Full Text] [Related]
7. The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer.
Sakin A; Sahin S; Atci MM; Sakin A; Yasar N; Geredeli C; Aksaray F; Cihan S
Pulmonology; 2021; 27(1):26-34. PubMed ID: 31839507
[TBL] [Abstract][Full Text] [Related]
8. Treatment Variation of Sequential versus Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer Patients in the Netherlands and Belgium.
Walraven I; Damhuis RA; Ten Berge MG; Rosskamp M; van Eycken L; de Ruysscher D; Belderbos JSA
Clin Oncol (R Coll Radiol); 2017 Nov; 29(11):e177-e185. PubMed ID: 28780009
[TBL] [Abstract][Full Text] [Related]
9. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
Dieleman E; van der Woude L; van Os R; van Bockel L; Coremans I; van Es C; De Jaeger K; Knol HP; Kolff W; Koppe F; Pomp J; Reymen B; Schinagl D; Spoelstra F; Tissing-Tan C; van der Voort van Zyp N; van der Wel A; Wijsman R; Dielwart M; Wiegman E; Damhuis R; Belderbos J
Clin Lung Cancer; 2023 Mar; 24(2):130-136. PubMed ID: 36572596
[TBL] [Abstract][Full Text] [Related]
10. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Gómez Rueda A; Taus Á; Álvarez Álvarez R; Bernabé-Caro R; Chara L; López-Brea M; Vilà L; Sala González MÁ; Del Barrio Díaz Aldagalán A; Esteban Herrera B; López Castro R; Álvarez Cabellos R; Doménech M; Falagan S; Moreno Vega A; Aguado C; Barba A; Delgado Ureña MT; Isla D; Bellido Hernández L; Fírvida Pérez JL; Juan-Vidal Ó; Massutí B; Mielgo-Rubio X; Ortega AL; Catot S; Dómine M; Escoín-Pérez C; García Navalón F; Gil-Bazo I; Muñoz S; Rodríguez-Abreu D; Villatoro Roldán RM; Alonso-Jáudenes Curbera G; León-Mateos L; Padilla A; Paredes Lario A; Sánchez-Torres JM; Garrido P;
Clin Transl Oncol; 2024 Jul; 26(7):1779-1789. PubMed ID: 38512450
[TBL] [Abstract][Full Text] [Related]
11. Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer.
Hung A; Lee KM; Lynch JA; Li Y; Poonnen P; Efimova OV; Hintze BJ; Buckingham T; Yong C; Seal B; Kelley MJ; Reed SD
BMC Cancer; 2021 Jul; 21(1):824. PubMed ID: 34271861
[TBL] [Abstract][Full Text] [Related]
12. Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer.
Bobbili P; Ryan K; DerSarkissian M; Dua A; Yee C; Duh MS; Gomez JE
PLoS One; 2020; 15(3):e0230444. PubMed ID: 32187231
[TBL] [Abstract][Full Text] [Related]
13. Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer.
Conibear J;
Br J Cancer; 2020 Dec; 123(Suppl 1):10-17. PubMed ID: 33293671
[TBL] [Abstract][Full Text] [Related]
14. Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec.
Agulnik J; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Lecavalier M; Small D
Curr Oncol; 2020 Oct; 27(5):e459-e466. PubMed ID: 33173385
[TBL] [Abstract][Full Text] [Related]
15. Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial.
Bi N; Liang J; Zhou Z; Chen D; Fu Z; Yang X; Feng Q; Hui Z; Xiao Z; Lv J; Wang X; Zhang T; Wang X; Deng L; Wang W; Wang J; Liu L; Hu C; Wang L
JAMA Netw Open; 2019 Dec; 2(12):e1918070. PubMed ID: 31851351
[TBL] [Abstract][Full Text] [Related]
16. Treatment of unresectable stage III NSCLC: Real world cohort study and literature review.
Verfaillie S; Lambrecht M; Berkovic P; Dooms C; Nackaerts K; Van de Velde AS; Vansteenkiste J; Wauters E
Cancer Treat Res Commun; 2023; 36():100727. PubMed ID: 37307680
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and survival outcomes in older adults receiving concurrent or sequential chemoradiation for stage III non-small cell lung cancer in Alliance trials (Alliance A151812).
Maggiore RJ; Zahrieh D; McMurray RP; Feliciano JL; Samson P; Mohindra P; Chen H; Wong ML; Lafky JM; Jatoi A; Le-Rademacher JG
J Geriatr Oncol; 2021 May; 12(4):563-571. PubMed ID: 32950428
[TBL] [Abstract][Full Text] [Related]
18. Retrospective cohort study of unresectable stage III non-small-cell lung cancer in Canada.
Seung SJ; Hurry M; Walton RN; Evans WK
Curr Oncol; 2020 Aug; 27(4):e354-e360. PubMed ID: 32905267
[TBL] [Abstract][Full Text] [Related]
19. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.
Honglian M; Zhouguang H; Fang P; Lujun Z; Dongming L; Yujin X; Yong B; Liming X; Yirui Z; Xiao H; Jin W; Yue K; Lvhua W; Ming C
Thorac Cancer; 2020 Apr; 11(4):898-906. PubMed ID: 32068962
[TBL] [Abstract][Full Text] [Related]
20. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
